SecBot SecBot
SECBOTREPLAY Home › Report › DRTS

DRTS · REGAIN trial: 100% ORR in GBM

Alpha Tau Medical Ltd. · PRESS-RELEASE filed Nov 15, 2026 at 13:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Nov 15, 2026 at 13:00 ET

Alpha Tau Medical announced updated interim results from its REGAIN trial of Alpha DaRT for recurrent glioblastoma, showing all eight treated patients alive, 100% objective response rate in evaluable patients (83.3% complete responses), and no unanticipated serious adverse events. The data were presented at the SNO annual meeting and suggest strong early efficacy in a devastating cancer with an average survival of 8 months.

  • All eight treated patients alive as of November 11, 2026; median overall survival not reached
  • Six evaluable patients: 100% objective response rate (5 complete responses, 1 partial response)
  • No unanticipated serious adverse events; primary feasibility and safety endpoints met
  • Trial enrolling toward 20 patients; initial discussions suggest data may support market submission

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access